The short answer

For most people, “compounded semaglutide” from a telehealth shop is no longer a legal option in 2026. The FDA declared the national semaglutide shortage resolved in February 2025, which triggered grace periods for compounding pharmacies that have since expired. Mass compounding — the kind that supplied millions of telehealth patients in 2023–2024 — is over. What remains is a narrow, patient-specific exception, plus a fast-moving brand-name market that now includes an oral option. Here’s how the two actually differ today.

What ended, and when

Semaglutide and tirzepatide were in genuine national shortage for years, which let FDA-registered 503A pharmacies and 503B outsourcing facilities compound versions of both drugs under a shortage exception. That exception ran out on a strict timeline:

• FDA determined the tirzepatide shortage was resolved in late 2024 and affirmed that determination in December 2024, starting a short compounding transition window.
• FDA determined the semaglutide shortage was resolved in February 2025, starting a similar transition window for that drug.
• By mid-2025, the enforcement-discretion grace periods for both drugs had expired for 503A pharmacies and 503B outsourcing facilities alike.
• On April 30, 2026, FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely — closing a separate compounding pathway some outsourcing facilities had continued to use. The public comment period on that proposal closed June 29, 2026, with a final decision still pending as of this article.

The practical effect: the mass-market compounded semaglutide + B12 vials that filled telehealth ads in 2023–2024 are, in FDA’s own description, “essentially a copy” of the approved product — and copies of a non-shortage drug are not a legal compounding basis.

What’s still legally compounded

A narrower carve-out survives: patient-specific compounding under Section 503A, where a prescriber documents a real clinical reason the commercial product won’t work for a specific, named patient — for example:

• A documented allergy or sensitivity to an inactive ingredient in the branded product.
• A need for a dose or formulation that isn’t commercially available.
• A physical or cognitive limitation that makes the standard injector unusable.

This is a case-by-case medical decision a licensed provider makes with a specific patient in front of them — not a standing product a telehealth company can advertise and ship at scale.

The brand-name side has changed too

• Injectable brands — Wegovy (semaglutide) and Zepbound (tirzepatide) — remain widely available at retail pharmacies, and manufacturer cash-pay programs have brought effective monthly costs down from list price for many patients: NovoCare’s Wegovy program has offered tiers roughly in the $149–$399/month range depending on dose, and LillyDirect’s Zepbound program has offered roughly $299–$499/month depending on dose. These programs change often — confirm current pricing directly with the manufacturer or your provider.
• Oral Wegovy — FDA approved an oral semaglutide tablet for weight management in December 2025, and Novo Nordisk launched it in the US in January 2026, adding a needle-free brand-name option that didn’t exist during the compounding boom.

Red flags to watch for

• Any seller offering “semaglutide” without requiring a prescription or a clinical evaluation.
• “Research chemical” or peptide-vendor listings for semaglutide — these operate outside pharmacy regulation entirely, regardless of what a website’s disclaimers say.
• Telehealth intake that never asks about your specific clinical history or why a commercial product wouldn’t work for you — that’s the exact question FDA now requires a patient-specific compounding pharmacy to answer.

The next step

If a commercial GLP-1 product isn’t working for you — cost, side effects, or access — the compliant path is a conversation with a licensed provider about whether you qualify for patient-specific compounding, a manufacturer savings program, or a different approved option. See our guide on how to get peptides prescribed for the general access process, and check the legal status tracker for where things stand today.

Sources

• FDA — “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize”
• FDA — Declaratory Order, Resolution of Shortages of Tirzepatide
• Pharmacy Times — “FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding”
• Orrick — “FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs”
• AJMC — “FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss”

← All articles